Note: Descriptions are shown in the official language in which they were submitted.
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
TITLE OF THE INVENTION
COLLOID COMPOSITIONS FOR SOLID PHASE BIOMOLECULAR
ANALYTICAL, PREPARATIVE AND IDENTIFICATION SYSTEMS
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the priority of U.S.
Provisional Application No. 60/201,908 filed May 4, 2000
entitled, NOVEL COLLOID COMPOSITIONS USEFUL IN THE
PREPARATION OF SOLID PHASE BIOMOLECULAR ANALYTICAL
PREPARATIVE AND IDENTIFICATION SYSTEMS, the whole of
which is hereby incorporated by reference herein.
STATEMENT REGARDING FEDERALLY SPONSORED
RESEARCH OR DEVELOPMENT
Part of the work leading to this invention was
carried out with United States Government support
provided under a grant from the National Institutes of
Health, Grant No. 1R.43CA80579-01. Therefore, the U.S.
Government has certain rights in this invention.
BACKGROUND OF THE INVENTION
Various polymer-based, solid support and/or porous
matrix systems are in common use in molecular biology
research, genetic analysis and diagnosis. In these
systems, a biopolymer, such as a specific antibody or a
nucleic acid for an antigen-antibody binding
determination or a nucleic acid hybridization analysis,
respectively, is used as an analytical probe, and affixed,
-1-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
e.g., to a porous matrix which may be layered on a solid
support. The material of a porous matrix commonly
consists of a highly charged polymer such as
nitrocellulose, activated nylon, polyvinyl difluoride
(PVDF) or agarose beads as shown in Chin et al., U.S.
Patent No. 6,197,599. In other such biopolymer probe
systems used for microarray analysis, for example U.S.
Patent No. 5,744,305 (Fodor et al.), the probe of
interest is chemically reacted with a solid surface and a
biopolymer probe-binding matrix, such as nitrocellulose,
is not required.
Such systems are used, e.g., to identify or isolate
molecular species contained within a biological
preparation to be characterized. The species of interest
hybridizes or binds to the target biopolymer probes,
which are provided in a solid support form, such as in a
glass or plastic slide configuration.
Microarray technology is a recent application of
hybridization based approaches to analysis of nucleic
acids (DNA, cDNA, and RNA) in biological samples. This
technology is basically a miniaturization of the well-
known membrane hybridization technology introduced by
Southern and others in the 1970's. In this technology,
small volumes of different oligonucleotides or PCR-DNA or
cDNA samples are spotted or synthesized on a membrane or
a solid surface at very high densities to form a single
microarray. Each spot within the array contains replicate
copies of a single nucleic acid probe species (NAX,
wherein x varies according to the base sequence
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
composition of the nucleic acid) and the array consists
of a multiplicity of spots encompassing a collection of
different species (NAxl, NAx2, ...) , each of which is in a
known position in the spotted array. Such a microarray
can be hybridized to an unknown nucleic acid sample to
determine the degree of complementarily between the the
individual nucleic acids in the unknown sample and the
different, known nucleic acid species on the microarray.
Preparation of microarray systems of the prior art
is a very labor intensive endeavor, however. ~It would be
desirable to have additional ways to prepare such systems
that would require fewer steps on the part of the end
user and that would result in the reduction or
elimination of process-related. variability from
laboratory to laboratory.
BRIEF SUMMARY OF THE INVENTION
The compositions, systems and methods of the
invention provide the desired improvements over the prior
art. In one aspect, the invention is directed to a
liquid composition comprising a colloidal suspension of a
biomolecule-binding matrix material dispersed in a
liquid, with particles of the matrix material being of a
defined particle size, and replicate copies of a
biomolecule, which are distributed, preferably uniformly,
throughout the colloidal suspension and are bound to the
matrix material particles. The matrix material,
preferably, is nitrocellulose, polyvinyl difluoride or
-3-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
activated nylon, and the biomolecule, preferably, is a
biopolymer, most preferably a nucleic acid or a protein.
The liquid composition of the invention can be used
directly for sample analysis or preparation of
biomolecules, or aliquots of the composition can be
spotted onto a support to form a microporous matrix
system or microarray for analysis or preparation of
biomolecules. Aliquots of the liquid composition of the
invention can also be dried to produce a powder of
microfine particles (e. g., having diameters of less than
10 um and preferably 100-500 nm). This powder can be
applied to a solid support in a microarray pattern, e.g.,
by electrostatic printing, also to form a microarray of
the invention.
Compositions and microarrays according to the
invention are useful in any type of analytical or
preparative procedure relating to biomolecules. They are
particularly useful, e.g., in methods for detecting a
biomolecule analyte in a liquid sample, methods for
determining the presence of a particular nucleic acid
sequence within a liquid sample and methods for
determining the presence of a drug candidate molecule in
a liquid sample. Drug candidates identified using the
methods of the invention are also within the scope of the
invention. The invention further comprises kits for
practicing the various methods of the invention. For
example, a useful kit would include a particular
microarray according to the invention, and reagents and
instructions for practicing the specific method
-4-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
identified, the reagents being packaged in a convenient
easy-to-use format.
BRIEF DESCRIPTTON OF THE DRAWINGS
Other features and advantages of the invention will
be apparent from the following description of the
preferred embodiments thereof and from the claims, taken
in conjunction with the accompanying drawings, in which:
Figs. lA-1F show the components and principle of use
of a microarray according to the invention, specifically:
Fig. 1A is a drawing of a microscope slide having
thereon a colloidal microarray according to the
invention;
Fig. 1B is an exploded view of a typical spot of the
microarray of Fig. 1A showing that the spot is composed
of a large number of colloidal particles of the matrix
biomolecule:
Fig. 1C is an exploded view of a single colloidal
particle of Fig. 1B showing the particle coated with
antigen;
Fig. 1D is an exploded view of the single colloidal
particle of Fig. 1C showing a bound antigen probe;
Fig. 1E shows the antigen probe molecule of Fig. 1D
after binding to a specific antibody present in a test
sample;
Fig. 1F shows the antigen/antibody combination of
Fig. 1E bound to a detector fluorophore. The intensity
of the fluorophore signal is used as a measure for the
level of different antibodies in the test sample; -
_5_
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
Fig. 2 is a micrograph scan of colloidal particles,
such as in Fig. 1C, less than 45 um in diameter;
Fig. 3 is a worksheet for generic HLA-DR SSOP
typing;
Fig. 4 is a micrograph of three microarrays
according to the invention showing the results of HLA
typing of three different individuals; and
Fig. 5 is a micrograph of three microarrays
according to the invention showing antibody profiles
against a variety of antigens for three different
individuals.
DETAINED DESCRIPTION OF THE INVENTION
This invention relates to new liquid colloid-based.
compositions containing biomolecules, e.g., proteins,
nucleic acids, or other biopolymers of interest, bound to
particles of a matrix material. The compositions of the
invention are useful in the preparation of solid support,
polymer-based, porous matrix analytical or preparative
systems for identification, isolation, detection,
characterization andlor analysis of biological specimens,
which specimens may contain species of biomolecules
(targets) that specifically bind to or associate with the
biomolecules, or probes, in the composition. In two
particular embodiments, the invention is directed to
systems for nucleic acid or protein characterization and
specifically to the means and methods for preparing
analytical or chromatographic/preparative systems such as
analytical nucleic acid or protein-based microarrays or
-6-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
preparative affinity-based separation materials,
respectively.
In prior art systems, probes are deposited on a
solid support, e.g., in the pattern of a microarray and,
subsequently, cross-linking and blocking steps are
carried out on the preformed probe/solid porous matrix
complex within the microarray as part of an analytical
procedure. In the prior art, the solid matrix is
prepared at the point of manufacture, usually in a slide
or membrane format. At the end user level, the probe is
then added. The assembly process continues with the
cross-linking of the probe within the polymer matrix and
then the reduction of non-specific background binding by
blocking out with non-specific nucleic acids and/or
proteins to cover sites within the polymer matrix to
which the probe is not bound.
In the system of the invention, however, the probe
is added to the colloid-based matrix material in liquid
composition format before the composition is spotted on a
solid support. Moreover, cross-linking and blocking
steps may be carried out either before or after the probe
biopolymer-containing solid matrix is formed. This
flexibility provides th.e opportunity of performing these
steps at the point of manufacture rather than at the end-
user laboratory stage of product use. It is well known
that the cross-linking and blocking steps in the
laboratory are associated with both time-consuming sample
processing and great variability in final results from
run to run within a given laboratory and between
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
laboratories. Of particular importance is that the
failure to block out non-specific binding sites of the
matrix may contribute to background signals that
adversely effect analytical discrimination between probe-
s specific and non-probeJnon-specific binding. These
variations in prior art systems lead to undesirable
disparities of results among different analyses of the
same unknowns.
Thus, an advantage of this invention is to provide
for the bulk spotting of microarrays and the elimination
of process-related variations by preparing the analytical
systems, such as nucleic acid microarrays, with cross
linking and blocking steps all to be carried out at the
manufacturing level. Thus, uniform quality control of
the microarray slides at the point of manufacture is
possible so that each spot contains a specific
crosslinked and background-blocked probe. This allows
different laboratories to conduct analyses with replicate
probe-solid support systems of probes without the time-
consuming and error-related cross-linking and blocking
steps.
The system of the invention has utility, e.g., for
oligonucleotides, full length cDNAs and oligopeptides, as
well as for large full length proteins, i.e., any
biopolymer that can be made to carry a charge. For this
reason, it offers the advantage of greater versatility in
preparing microarrays for more applications than can be
provided by prior art microarray systems, which are
-g_
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
prepared with de novo synthesis of the respective nucleic
acid/biopolymers for each spot.
For the purposes of illustrating some of the
advantages of this invention, its use is described
particularly in the preparation and use of DNA and
protein microarrays. However, as will become obvious to
those skilled in the art, comparable advantages and
benefits will be apparent in the use of the liquid
compositions of this invention to prepare other solid
support systems such as in high surface area affinity-
based separation methods or analyses. In a further
aspect of this invention, the liquid colloid-based
compositions of the invention are used directly to
facilitate separation processes, e.g., isolation or
detection systems, carried out under liquid or fluid
conditions. For example, liquid polymer-based
compositions of the invention could be used in a slurry
form for contacting and allowing the binding of compounds
from a sample of interest, and then polymer matrix-based
fractions could be centrifuged out and washed. The bound
selected species of interest could then be isolated from
the matrix material. Alternatively, polymer matrix-based
material can be formed as a packing material for an
affinity chromatographic-type column in analytical and/or
preparative procedures.
Thus, in certain preferred embodiments, the
invention provides for a novel composition useful in the
preparation of nucleic acid or protein microarrays on
solid supports, e.g., glass or plastic microscope slides.
_g-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
Preferred embodiments of the composition of the invention
contain at least the following three components:
{i)replicate copies of, e.g., a nucleic acid fragment
{oligonucleotide or full length cDNA}; {ii} a polymer
composition, such as nitrocellulose, that is capable of
forming a generally porous molecular matrix and of
binding to the nucleic acid; and (iii) a liquid within
which polymer molecules and bound nucleic acid probes are
uniformly dispersed in colloidal suspension.
Preferably, the composition also includes, as a
fourth component, blocking reagents such as protein or
non-specific DNA, which are added after the nucleic acid
and polymer are equilibrated in the desired proportions.
Most preferably, the blocking reagents occupy all non-
specific binding sites so that only the probe, e.g.,
single stranded nucleic acid, is available for binding to
material in a sample to be tested. The ratio of the
concentrations of the nucleic acid and polymer in the
composition are preferably predetermined so as to obtain
a desired hybridization condition and/or to optimize the
signal desired in final analytical analysis. This ratio
may also be optimized to provide the maximum amount of
nucleic acid probe and a minimum amount of polymer
matrix.
The composition of the invention makes possible a
method of making a nucleic acid microarray wherein each
different spot, which individually contains replicates of
a given probe species, NAX, is derived from a common
liquid composition preparation so that there is no
-10-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
variation from spot to spot. Furthermore, using the
composition of the invention, it is possible to make a
nucleic acid microarray wherein each spot has a
specifically determined concentration of oligonucleotide
and wherein the actual molar concentration of the oligo
or cDNA species for the respective spots of the
microarray may not be equal in order to optimize the
characteristics of the entire array to obtain certain
desired performance parameters, e.g., a uniform
analytical signal among the spots, in order to achieve a
desired uniformity in hybridization temperature
conditions.
The ratio of the concentration of oligonucleotide
probe to the concentration of polymer matrix material is
established so that the analytical signal of positive
hybrids can be optimized by minimizing the amount of
polymer present. Thus, a microarray can be prepared in
which the amount of polymer may be varied as desired from
spot to spot, e.g., the amounts of polymer for spots of a
given NAx species are equal, but the amount of polymer for
spots of different species (NAX1 and NAXZ} could be
different. Spotting compositions according to the
invention can be prepared so that certain conditions for
use of the resulting microarray, e.g., hybridization melt
temperature, may be selected in part by including an
additional component or by carrying out a physical or
chemical treatment of the spotting composition. Thus,
the microarray designer is provided with a variable
composition parameter wherein hybridization conditions
-11-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
can be adjusted by something other than the base
composition of the oligonucleotide.
The following examples are presented to illustrate
the advantages of the present invention and to assist one
of ordinary skill in making and using the same. These
examples are not intended in any way otherwise to limit
the scope of the disclosure.
EXAMPLE I
Preparation of a generic composition according to the
invention and use of the composition for preparation of a
microarray
The first step in implementing the improvements
possible with assay systems according to the invention is
to prepare a colloidal suspension of defined particle
size matrix material from, e.g., a highly charged
material such as nitrocellulose, activated nylon or
polyvinylidene difluoride. These materials are capable
of binding or adsorbing a variety of charged molecules
such as nucleic acids, proteins, etc., and such binding
is sufficiently strong to survive the high stringency
conditions required for hybridization reactions. The
matrix material in colloidal suspension could also be a
non-charged polymer, such as plastic, nylon or
polysulfone. The colloids are prepared by using any
number of traditional methods that may include
pulverization, precipitation and spray drying, as well as
a variety of other well-established techniques.
-12-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
To aliquots of this stable colloidal suspension in
water (or buffer) are added replicate copies of
individual probes. The substrate probe of interest can
be bound by ionic and non-ionic as well as covalent and
non-covalent bonds to the matrix material, These
substrates include but are not limited to proteins,
glycoproteins, polysaccharides, peptides, hormones,
vitamins, drugs, single or double stranded DNA, RNA, and
oligonucleotides. Individual substrates or combinations
of different substrates are mixed with the colloid
suspension and incubated for at least one hour at room
temperature in appropriate solution.
Then, binding sites on the highly charged matrix
material not occupied by molecules of the probe can be
blocked with any of the known blocking agents. To assure
complete saturation of the binding sites on the surface
of the colloidal particles, a blocking step is required,
and the colloid/substrate mixture is incubated with
excess blocking solution, which may contain non-specific
proteins such as milk or non-specific DNA such as salmon
sperm DNA. At this stage the colloid/substrate
preparation can be stored for extended periods of time.
The desired number of probe-containing (and
preferably blocked) liquid compositions are spotted on a
solid support (e. g., a slide, porous bead or flexible
tape made, e.g., from glass, plastic or polycarbonate)
and are allowed to dry and bind to the support. The
support can have any physical or chemical surface
modification appropriate for the intended use. For
-l3-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
example, a flat surface can be modified to include wells,
protrusions, or channels. Individually prepared solid
supports, e.g., microscope slides, are then used, e.g.,
in a reverse sequence-specific oligonucleotide probe
hybridization protocol or for the determination of
ligand/protein interactions.
The novel probe-treated and blocked colloidal
suspensions are also useful separately, e.g., to isolate
specific sequence-containing nucleic acids that hybridize
to the attached nucleic acid probe of interest. For
example, a probe-containing emulsion or colloid can be
exposed to a sample with a mixture of heterogeneous
nucleic acid and then centrifuged and washed. The
isolated nucleic acid is then removed from the attached
probe, e.g., by heating.
Specifically, in a typical reverse sequence-specific
oligonucleotide probe hybridization protocol array
preparation according to the invention, nitrocellulose
powder (e.g., from Aldrich Chemical Co.) is dissolved in
an organic solvent such as acetone or in a mixture of
organic solvents such as acetone-butanol-ethanol, etc.
The clear nitrocellulose solution is added to a large
volume of a polar solvent, such as water, in such a way
that a major fraction of the dissolved nitrocellulose
forms a milky colloidal suspension of nitrocellulose,
e.g, with heating and continuous mixing. The polymer in
this solution precipitates out of the water/organic
mixture in a colloidal form. This colloid is either
filtered through a specific pore size membrane (e. g.,
-14-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
standard Nalgene or Millipore filter units having pore
diameters of 0.20 - 0.45 Vim) or centrifuged and re-
suspended in a buffer such as 3xSSC, at a final
concentration of 100-50o nitrocellulose. Typically, a
preparation containing nitrocellulose at concentrations
ranging from 10 to 400 (v/v) in aqueous solution yields
colloidal particles having diameters ranging from
approximately 0.2 to 0.4 um. The precipitated or filter-
collected colloidal particles may be treated to improve
their utility by acid contact or acid washing (e. g., with
nitric acid). The colloidal particles are then washed
free of acid and resuspended in an aqueous medium.
An aqueous preparation of the biopolymer or
biomolecule probe of interest is then provided. This
preparation may also contain other components. For
example, a known concentration of a reference chromophore
or dye material, such as Fast Green (Amresco), having an
optical detection wavelength different from that of the
fluorophore-labeled biomolecule analyte to be detected
may be included. Such a reference chromophore would
serve as a detection marker to determine the quantity of
probe biomolecule deposited in a specific spot of a
microarray, as may be useful for manufacturing quality
control purposes. This dye marker could also serve as a
reference internal standard for quantitating the optical
signal of the fluorophore-labeled biomolecule analyte
bound to a specific probe in microarray analysis. In a
similar manner, a different dye marker could be added to
the colloidal preparation before biopolymer addition and
-15-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
used to track the concentration of matrix material from
the colloidal preparation through the various preparative
procedures.
Different aliquots of the colloidal preparation are
then each combined with a known quantity of a solution of
a specific probe, and the combined solutions are allowed
to incubate so that the biomolecule probe binds to the
surfaces of the colloidal particles. For nucleic acid
assays, the bound nucleic acid probes are preferably then
"crosslinked" to the nitrocellulose matrix particles. In
this context, "crosslinking" means exposing the colloidal
suspension to, e.g., UV light or heat. This treatment
causes the probe to lose tertiary structure and bind non-
covalently to the highly charged polymer matrix support.
After the probes have been allowed to bind to the
colloidal particles, blocking may be carried out to
completely saturate the unoccupied binding sites of the
colloidal particles with, e.g., non-specific DNA and/or
protein as appropriate. After this blocking incubation,
it may be desirable to wash the preparation to remove
excess probe and blocking reagents.
Following the blocking step, other components may be
added to the particle/prob,e preparation. For example, it
may be desirable to add a surfactant to the preparation
for the purpose of enhancing the deposition of the
particle/probe liquid solution onto solid support
surfaces such as glass or plastic slides. Surfactants
could include Tween 40, detergents or the like. Only
those surfactants that would not be expected to interfere
-16-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
with the assay procedures would be selected. In addition,
agents to promote the adhesion of the colloidal particles
to a solid support surface could also be included.
The colloidal particle/probe samples were then
placed in individual wells of a 96 well microtiter plate,
and the samples were spotted using a GMS 417 Arrayer
equipped with a 4-pin head. A single loading of the ring
used to produce up to 400 spots per pin on the surface of
a glass microscope slide. Arraying was carried out at
room temperature, in a constant humidity environment,
with the instrument protected from dust. The instrument
in its actual operating mode washed each pin with water
and ethanol and air dried the pins inbetween acquiring
each different oligonucleotide sample. Array spots were
placed at a center to center spacing of 300 um. The
identity and location of the oligonucleotide spots were
tracked by computer.
The slides were allowed to dry at room temperature
and then incubated in a sealed chamber containing a
binding solution, such as 10-30o(V/V) acetone in water.
Exposure to vapor of such a binding solution ensures
proper adhesion of the spotted composition to the solid
support as well as solidification of the composition of
the spot. Referring to Figs. 1A-1F, a representation of
the make-up of an individual spot in an array, it can be
seen in enlargement drawing Fig. 1B that, as a result of
this incubation, the particles of nitrocellulose in the
colloid bind to each other and to the solid support while
still retaining their particular binding properties. The
-17-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
bound particles as a group form a porous structure so
that the surfaces of the individual particles of
nitrocellulose are exposed. A micrograph scan of
colloidal particles according to the invention is shown
in Fig. 2.
Following the blocking step, the slides are heated
in an oven to dry and are ready to be used. For example,
in a determination of the genotypes of unknown samples,
each slide containing an array of spots of different NAX
could be hybridized to an unknown nucleic acid sample to
determine the degree of base complementarity between the
sample and any of the characterized probe spots on the
slide. For the HLA typing example described in Example
III, thirty-two sequence specific oligonucleotide probes
were used to assign intermediate level resolution HLA-
DRB1 alleles.
EXAMPLE II
Determination of protein/ligand interactions
Binding reactions between proteins and ligands can
be evaluated easily using the system of the invention,
e.g., as a means of obtaining useful information for
diagnostic or research purposes. Furthermore, in drug
discovery and development, the measured ligand/protein
interactions can be determined in the presence of
potential inhibitors or enhancers of selected
protein/ligand binding. Specifically, e.g., antigen, for
example, hepatitis B surface antigen, tetanus toxoid or
viral antigens can be bound to the colloid matrix
-18-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
particles and used to detect specific antibody. Also,
specific antibody can be bound to colloid to detect
antigen.
In one embodiment, a spotting composition is
preparedacCOrding to Example I to include a protein of
interest or a segment thereof, that contains a ligand
binding site. The composition is then treated with non-
specific blocking agents, as in Example I. Microarray
spotted slides are formed by deposition of very small,
well defined amounts of the preparation on a suitable
solid such as a glass or plastic slide. Such microarrays
can contain a variety of concentrations of the protein of
interest as well as internal controls such as proteins of
various degrees of amino acid sequence variation.
Under suitable incubation conditions, the protein
binding assay microarray slide can be incubated first
with a mixture of ligands that might potentially bind to
the proteins of the microarray. Chemical or physical
conditions of incubation could be selected to eliminate
non-specific binding and to establish a minimum binding
energy threshold in order to select or detect ligands
with a predetermined specificity and strength of binding
to the protein probe in the microarray. Furthermore, a
large number of different colloid/substrate preparations
can be spotted in a microarray format and the presence or
absence of a very large number of ligands present in a
single sample can be determined simultaneously.
An assay is then -carried out to identify those
microarray spots in which significant binding has
-19-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
occurred. One technique is to contact the microarray
slide a second time with an optically labeled ligand of
well characterized binding properties. In the absence of
a binding ligand in the mixture of unknowns, the labeled
ligand would bind to the protein of interest. This
binding can be detected by a suitably designed optical
scanner. On the other hand, the absence of or reduction
of signal intensity of the known ligand would indicate
the presence of a potential binding ligand in the mixture
of unknowns to be assayed.
Such a protein microarray would be applicable in
evaluating, e.g., antibody/antigen interactions, adhesion
molecule/ligand binding or enzyme/substrate interaction
and the like. In addition, non-optical assays involving
radiometric determinations could be employed in some
cases, in combination with well known
radioautoradiographic analytical methods to assay
binding.
EXAMPLE III
2 0 HhA typ3.ng
Although the membrane based system of the prior art
has been a useful research tool and has been used for
routine human leukocyte antigen (HLA) typing analysis, it
is a cumbersome, manual procedure:.that is labor intensive
and inefficient. Using the system of the invention,
however, a much more convenient method for routine HLA
typing can be devised. The new method comprises
conventional isolation of genomic DNA from an individual
and amplification of the HLA gene of interest using
-20-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
specific HLA primers. In addition, an HLA microarray can
be made with each spot being formed from a liquid
colloidal composition according to this invention,
wherein the probe of each spot is a sequence specific
oligonucleotide that is complementary to a region of a
known HLA polynucleotide sequence. A plurality of such
probes representing a plurality of the hypervariable
regions were used. For example, for intermediate level
resolution HLA-DRB1 typing, 32 probes, characterized in a
"Worksheet for Generic HLA-DR SSOP Typing," shown in Fig.
3, were used to assign DRB1 alleles. Hybridizing the
single stranded or denatured HLA PCR amplicon from an
individual with the probes spotted will produce distinct
patterns wherein only probes having complementarity with
the single stranded DNA will hybridize. Labelling the
hybridized single stranded HLA amplicon with an optical
or other detectable label allows the analysis and
interpretation to be fully automated based on the
comparison of the pattern of positive signals. Referring
to Fig. 4, the results of HLA typing of three different
individuals are shown. The specific hybridization
pattern for each individual can be located on the
worksheet shown in Fig. 3 and the HLA alleles determined.
EXAMPLE IV
A protein target microarray
Protein microarrays were prepared by binding to a
nitrocellulose colloidal suspension each of the following
antigens: hepatitis B surface antigen (HBsAg), tetanus
-21-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
toxoid, rubeola( measles), Varicella-Zoster virus (VZV),
diphtheria, human cytomegalovirus (HCMV), and
Helicobacter pylori (H. pilori). The binding was carried
out by incubating three different dilutions of each of
the antigens with a colloidal suspension for one hour at
room temperature, at pH 7.4. The amount of antigen
varied from 2 ug to 10 ug per 10 mg nitrocellulose
colloid. A non-specific protein, e.g., 5o milk protein
or 5o bovine serum albumin, was added to the
colloid/antigen mixture and incubated for several hours
to block the remaining free binding sites. A spotting
microarrayer was used to spot 3 n1 each of the blocked
colloid/antigen mixture on a glass microscope slide.
To test for the presence of antibodies for these
antigens in human serum samples, a number of test serum
samples were diluted in blocking solution, added to the
slide and incubated at room temperature for at least one
hour. After this incubation, the slides were washed at
room temperature with phosphate buffered saline (PBS)
containing 0.5o Tween 20 and 2X with PBS containing 0.50
Tween 20 and 0.1o milk protein.
To detect for the presence of bound human antibody
to each of the microspots in the array, a secondary
antibody, e.g., anti-human IgG that was fluorescently
labeled with Cy3, was then added to the slide and
incubated at room temperature for one hour. The slide was
then washed in PBS containing 0.5o Tween 20 and scanned
using a laser scanner (Affymetrix 418). To determine the
amount of human antibody bound to each of the antigens
-22-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
tested on the array, the fluorescence intensity level for
each spot was measured and compared to the negative and
positive control spots on the slide.
Examples of the antibody profile for these antigens
from the sera of three individuals are shown in Fig. 5.
EXAMPLE V
Reduction in Background Fluorescence
Another advantage of using colloidal nitrocellulose
for the preparation of microarrays is that the background
non-specific fluorescence of the resulting microarray is
significantly lower than that of the current commercially
available slides coated with a layer of nitrocellulose as
in the prior art. According to prior art methods, the
nucleic acid analyte of interest, which is to be detected
by hybridization to a nucleic acid probe, includes an
optically detectable fluorophore or fluorescent molecule.
This labeled analyte is added as a marker to a biological
sample believed to contain the analyte of interest.
After incubation of the biological sample with the
microarray and hybridization of analyte from the sample,
the unhybridized portions of the sample are washed away.
The presence of the analyte of interest, e.g., nucleic
acid, hybridized and bound to probe molecules, can then
be determined. The fluorophore of the nucleic acid
analyte marker is detected by exciting the marker
fluorophore at one wavelength and detecting the emitted
fluorescent signal with a suitable microarray optical
detection and analysis system.
-23-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
In prior art biomolecule-binding solid support
matrices, there is ordinarily a vast excess of binding
matrix such as fluorescent nitrocellulose. Such
materials contribute significant levels of background
fluorescence, and this diminishes their usefulness for
microarray-based analysis, especially when only very
small quantities of the analyte to be detected are
present in the sample. This example demonstrates a
comparison of background fluorescence present in a
biomolecule-binding matrix of the prior art, such as
nitrocellulose membranes deposited on glass slides as
taught by Chin (U.S. Patent No. 6,197599), with that of v
spots on a microarray according to the invention under
equivalent conditions.
Specifically, an area of a microarray spot of the
invention of known diameter is examined for fluorescence
at three different excitation and emission wavelengths
corresponding to three commonly used fluorophores
typically incorporated into nucleic acids in a sample the
DNA content of which is to be analyzed. In order to
enhance the range of detection of the microarray,
particularly at very low levels of analyte, it is most
desirable to minimize background fluorescence noise.
Spots of equivalent diameter were examined and the values
of emitted fluorescence were compared to produce a ratio
of gain by dividing the background fluorescence of a spot
on a conventional, prior art nitrocellulose-coated slide
(e.g., Grace BioLabs) to that emitted by a spot of the
same diameter on a microarray of the invention. The data
-24-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
obtained with a Genetic Micro Systems microarray analyzer
are shown in Table 1 below:
Table 1
Fluorophore nm nm Ratios Ratios
ExcitationEmission of of
Gain* Gain+
Cy3 550 565 178 61
Cy5 650 670 17 22
R-phycoerythrin480 578 178 56
*The ratios of gain are the ratios of the values of the settings of the
detection
circuit in order to obtain similar signal for the two types of slides, using
an
electronic setting reference.
+The ratios of gain in this column were based on use of reference fluorescence
of the respective glass slide supports.
The results show that for equivalent size spots
using the excitation wavelength for Cy3 fluorophore, a
blank spot of a conventional nitrocellulose membrane
coated slide of Grace BioLabs has 61 to 178 times the
amount of background fluorescence as a spot according to
the present invention of equivalent size and biomolecule-
binding capacity. Significant improvements by one or two
orders of magnitude using microarrays of the invention
are also observed for Cy5 and R-phycoerythrin
fluorophores. These three fluorophore exemplars are also
useful in microarrays for determining proteinlprotein
interactions.
-25-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
EXAMPhE VI
Comparative dimensions
In this example, the amount of biomolecule-binding
matrix material (e.g., nitrocellulose) required to
provide an equivalent binding surface area for the
bioanalyte according to the prior art is compared to the
amount of such matrix material used to produce colloidal
particles according to this invention that have the same
binding surface area for contacting the bioanalyte. As
is shown below, the reduction in background fluorescence
when microarrays according to the invention are used in
analytical methods as compared with microarrays of the
prior art is due in part to the reduction in thickness
(and, Consequently, in volume) possible for spots of the
same diameter.
With commercially available nitrocellulose-coated
glass slides (e.g., Grace Biolabs), a microarray spot of
150 um diameter typically has a nitrocellulose thickness
of 17 um or more. In contrast, an 150 um diameter
microarray spot prepared from a 250 (v/v)
nitrocellulose/aqueous solution according to the
invention has thickness of about 0.3 um. Therefore, the
amount of nitrocellulose present in a typical colloidal
microarray spot according to the invention is 0.3117, or
less than 2 0, of the nitrocellulose present in a spot on
the commercially available nitrocellulose-coated glass
slides. Spots having volumes of as little as 100 n1 or
less (e. g., 50 or 20 n1) are obtainable.
-2 6-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
Using a microarray according to the invention, a
practitioner can drastically reduce the amount of
nitrocellulose and its associated background fluorescence
without diminishing the biomolecule probe binding
capacity otherwise available. The reduction in thickness
of biomolecule-binding matrix agent (e. g.,
nitrocellulose) is associated necessarily with a
corresponding reduction in fluorescence background
during, e.g., protein binding detection with fluorophore-
labeled antibodies directed against protein analytes
bound to the antigen probes. This invention would,
therefore, provide greater sensitivity for this assay,
particularly for detection of very low levels of protein
analyte in a sample. Such very low concentration protein
analytes, as may occur in the detection of cancer cell
marker proteins in serum samples, may be undetectable
with prior art systems of inherently high fluorescence
background.
USE
Microarrays according to the invention can easily be
adapted for use in a variety of routine diagnostic
antibody/antigen-based assays commonly carried out in
liquid-based systems in clinical laboratories. For
example, blood bank laboratory procedures to determine
the presence of antibodies or antigens in the blood of a
potential donor could readily be determined. In this
case, the antigens of known pathogens, such as surface
proteins of the hepatitis virus, can be used as probes
-27-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
in microarray spots, and the donor's serum can be tested
for the presence of antibodies to the antigens. Also,
the presence of specific pathogens in the donor's blood
can be assayed by utilizing antibody probes that are
directed against the characteristic antigens of the
pathogens of interest. In the same manner, this
microassay-based method could be used to diagnose
infections as well as monitor the progress of antibiotic
or other therapy directed against the pathogens.
In another clinical application, in which
antigen/antibody-based assays are used, microarray slides
prepared according to this invention can be used to~
determine levels of therapeutic drugs (e.g., digoxin) or
drugs of abuse in a patient's serum. Such assays
currently utilize antibody/antigen-based determination
techniques. Microarrays of this invention can also be
used to detect proteins in a patient's serum, which
proteins are diagnostic of disease conditions. For
example, CA125 and PSA are protein markers of cancer
cells associated with ovarian and prostatic cancer,
respectively. Because of the expense associated with
commercially available immunoassay kits and procedures to
test for these antigens, these tests are most frequently
used only after the disease has occurred. With the use
of microarrays for these and other cancer antigens (e. g.,
breast, colon), such tests could be performed readily and
with greater facility than Current methods. The
availability of cancer detection microarray-based assays
according to this invention would also facilitate the
-28-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
routine monitoring of cancer therapy to track, e.g., the
protein or nucleic acid indicators or markers for various
types of cancer. The availability of this efficient
system to assay for many cancer markers in an efficient
and economic manner could promote earlier detection and
early treatment. Thus, microarrays prepared at the
point of manufacture as taught herein, instead of being
prepared at the user level, have the advantage of
providing many diagnostic laboratories with carefully
quality controlled-assay components and procedures and
thereby provide a common base to compare assay results
among thousands of different laboratories.
Microarrays of the current invention are also useful
for detecting abnormal serum protein and genetic
disorders associated with mutations present in
prospective parents, fetuses and newborns for early
prediction or detection of certain diseases, such as
cystic fibrosis. For this type of use, either protein
probe microarrays or DNA probe microarrays can be
constructed according to the invention to provide more
efficient and less expensive assay methodologies than are
commercially available now. Microarrays according to
the invention can also be used for diagnosis of
immunodeficiency diseases characterized by abnormal
antibody profiles of individuals with various immune
system disorders.
Microassays of the present invention can also be
prepared for use in drug discovery and basic research.
In one case, for example, a cell surface receptor or
-29-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
adhesion molecule, the involvement of which is associated
with a disease process such as the seminal formation of
athrosclerotic plaque such as in hardening of the
arteries, can be used as a probe in a microarray. Also,
in the same microarray, various closely related probes of
comparable but different compositional and structural
content could be deposited on the same microarray slide
format, for example. Then, solutions containing
potential drugs can be incubated with the microarray to
allow possible interaction with and/or binding to the
drug target of interest. In another embodiment, the
potential drugs themselves could be appropriately labeled
for detection. Such binding could also be assessed,
after the contact incubation, by subsequently exposing
the microarray to one or more fluorophore-labeled
antibodies. By analyzing the pattern of antibody binding
among the various target probe/microarray spots, one can
determine which potential drug candidates specifically
bind to the target of interest wherein such binding of a
drug candidate would interfere with the subsequent
binding of the fluorophore-labeled antibody to the target
probe.
It is a fundamental aspect of this invention, with
respect to the use of microarrays for clinical diagnostic
applications in thousands of different hospital and
commercial laboratories, that the analytical system has
the highest level of precision and accuracy with minimal
laboratory-to-laboratory variations when assaying the
same sample for a particular analyte. This invention
-30-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
succeeds in providing such a system by creating a novel
combination of the following elements not available in
prior art analytical systems, namely: [1] each spot for a
given probe and microarray position on many replicate
microarrays can be derived from the same lot of liquid
colloidal suspension composition at the point of
manufacture; [2] secondary microarray preparation steps,
such as blocking of the exposed biomolecule-binding sites
of the matrix material as well as cross linking the
nucleic acid probes within the binding matrix polymer
molecules, are performed in bulk at the point of
manufacture rather than at the user level; [3] the
thickness and amount of probe/liquid colloidal suspension
is kept to a minimum required for the assay so as to
optimally reduce background interference and maximize
assay sensitivity; [4] probe deposition onto the binding
matrix is performed on generally micro-spherical surfaces
of the matrix in a liquid medium so as to maximize the
amount of probe present relative to the amount of
potentially assay-interfering binding matrix; [5] an
internal standard reference standard, e.g., a dye or
chromophore, may be included in the liquid
probe/colloidal liquid suspension to provide a convenient
means to assess manufacturing quality; [6] the same
reference standard as in [5] , or a different chromophore
as may be preferred, has a defined. quantitative
relationship to the amount of probe actually deposited on
the microarray slide, and this may be used, if necessary,
to provide a means for normalization of assay results
-31-
CA 02408094 2002-11-04
WO 01/83825 PCT/USO1/14373
based on the known quantitative relationship of the
probe; and [7] multiple assays for different protein
analytes may be performed simultaneously with the
microarray of the invention, for example, a single
protein probe microarray (e. g., for many different types
of cancer cell markers) can be enclosed in a single probe
protein reaction chamber and treated sequentially with a
single patient serum sample, washed with a single wash
reagent and then treated with a single development
reagent, which development reagent contains a
multiplicity of fluorophore-labeled antibodies and then
analysed by a single microarray analysis instrument.
While the present invention has been described in
conjunction with a preferred embodiment, one of ordinary
skill, after reading the foregoing specification, will be
able to effect various changes, substitutions of
equivalents, and other alterations to the compositions
and methods set forth herein.
-32-
